BUZZ — Aquestive rises on US licensing deal for seizure drug with Eton Pharma

* Aquestive Therapeutics shares gain 4.3% to $4.87 premarket * The drugmaker says it licensed exclusive US rights to its Libervant to Eton Pharmaceuticals * The seizure treatment is expected to launch in April 2027, subject to final approval * Libervant, a dissolvable diazepam film placed inside the cheek, is designed for people who experience clusters of seizures; can offer alternative to nasal sprays, rectal medicines * Won FDA nod for patients aged two to five years in April * FDA reviewing application to expand usage to children ages 6 to 11; decision expected before April * Stock down 27% YTD (Reporting by Padmanabhan Ananthan) ((mailto:Padmanabhan.Ananthan@thomsonreuters.com)